Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 3/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9435964 | 0.85 | RAB9A (0.72) | MTNR1BPOLBTP53NPC1RAB9A | |
| SCHEMBL13480581 | 0.83 | MTNR1B (0.72) | MTNR1BRXFP1TP53TSHRNPC1 | |
| SCHEMBL13480580 | 0.83 | EPHX1 (0.69) | MTNR1BPOLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9428464 | 0.81 | MTNR1A (0.65) | MTNR1BPOLBRXFP1NPC1RAB9A | |
| SCHEMBL10070470 | 0.80 | MTNR1B (0.51) | MTNR1BPOLBTP53TSHRNPC1 | |
| SCHEMBL4058023 | 0.79 | NPC1 (0.56) | POLBRXFP1TP53TSHRNPC1 | |
| SCHEMBL8027073 | 0.79 | MTNR1A (0.63) | MTNR1BTP53TSHRNPC1RAB9A | |
| SCHEMBL11282040 | 0.78 | RAB9A (0.66) | MTNR1BPOLBTP53TSHRNPC1 | |
| SCHEMBL11782014 | 0.78 | POLB (0.55) | POLBRXFP1TP53NPC1RAB9A | |
| SCHEMBL4064359 | 0.76 | NPC1 (0.57) | POLBRXFP1TP53TSHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053108-B2 | Indoline compounds | LES LABORATOIRES SERVIER (FR) | 2006-05-30 | — | — | US | disclosed |
| EP-1348704-B1 | Indole derivatives as 5-HT2C antagonists, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2006-05-17 | — | — | EP | disclosed |
| US-6998403-B2 | Benzoindoline compounds | LES LABORATOIRES SERVIER (FR) | 2006-02-14 | — | — | US | disclosed |
| EP-1516871-A1 | Benzoindoline derivatives with adrenergic activity | Les Laboratoires Servier (FR) | 2005-03-23 | — | — | EP | disclosed |
| US-20050059675-A1 | Antidepressants; N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-1,2-dihydro-3H-benzo[e]indole-3-carboxamide; antagonist of adrenergic receptor, serotonin receptor; anxiety, schizophrenia, Parkinson's disease, cognitive disorders, schizophrenia | LES LABORATOIRES SERVIER (FR) | 2005-03-17 | — | — | US | disclosed |
| US-20040192736-A1 | New indoline compounds | LAVIELLE GILBERT (FR) | 2004-09-30 | — | — | US | disclosed |
| US-6759421-B2 | N-(3-PYRIDYL)-1,2-DIHYDRO-3H-BENZO(E)INDOLE-3-CARBOXAMIDE DERIVATIVES USEFUL AS A 5-HT2C ANTAGONIST | LES LABORATOIRES SERVIER (FR) | 2004-07-06 | — | — | US | disclosed |
| US-20030199555-A1 | Indoline compounds and to pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2003-10-23 | — | — | US | disclosed |
| EP-1348704-A1 | Indole derivatives as 5-HT2C antagonists, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199555-A1 | Indoline compounds and to pharmaceutical compositions containing them | TPH1, IDO1, HTR3A | MTNR1B 177/4885POLB 1820/4885RXFP1 232/4885 |
| US-20040192736-A1 | New indoline compounds | TPH1, HTR3A, HTR1D | MTNR1B 631/4885POLB 2093/4885RXFP1 186/4885 |
| US-20050059675-A1 | Antidepressants; N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-1,2-dihydro-3H-benzo[e]indole-3-carboxamide; antagonist of adrenergic receptor, serotonin receptor; anxiety, schizophrenia, Parkinson's disease, cognitive disorders, schizophrenia | HTR2C, HTR2A, ADRA2C | MTNR1B 138/4885POLB 2302/4885RXFP1 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.